Inhibition of corneal neovascularization by rapamycin

Experimental and Molecular Medicine

Volumn 38, Issue 2, 2006, Pages 173-179

  Young, Sam Kwon ^a   Jae, Chan Kim ^a  

^a Chung Ang University   (South Korea)

Author keywords

Cornea; Neovascularization; Rabbit; Rapamycin; Vascular endothelial growth factor

Indexed keywords

ORYCTOLAGUS CUNICULUS;

EID: 33646785007     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2006.21     Document Type: Article

References (31)

1. Adamis AP, Meklir B, Joyce NC. In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells. Am J Pathol 1991;139:961-7
2. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22
3. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994;63:265-311
4. Baker H, Sidorowicz A, Sehgal SN, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo) 1978;31:539-45
5. Barbet NC, Schneider U, Helliwell SB, Stansfield I, Tuite MF, Hall MN. TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 1996;7:25-42
6. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: models and modulators. Int Rev Cytol 1995;159:113-60
7. Connolly DT. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem 1991;47:219-23
8. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization. Pathogenesis and inhibition. Cornea 1987;6:250-7
9. Gomez-Cambronero J. Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett 2003;550:94-100
10. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis:involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35
11. Hill JC, Maske R. An animal model for corneal graft rejection in high-risk keratoplasty. Transplantation 1988;46:26-30
12. Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA, Germain GS, Abraham RT, Houghton PJ. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:886-94
13. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002;16:771-80
14. Jimi S, Ito K, Kohno K, Ono M, Kuwano M, Itagaki Y, Ishikawa H. Modulation by bovine angiogenin of tubular morphogenesis and expression of plasminogen activator in bovine endothelial cells. Biochem Biophys Res Commun 1995;211:476-83
15. Kim JH, Kim JC, Shin SH, Chang SI, Lee HS, Chung SI. The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF. Exp Mol Med 199931:203-9
16. Kobayashi N, Kabuyama Y, Sasaki S, Kato K, Homma Y. Suppression of corneal neovascularization by culture supernatant of human amniotic cells. Cornea 2002;21:62-7
17. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801
18. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci 2005;46:454-60
19. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977;55:48-51
20. Olsen TW, Benegas NM, Joplin AC, Evangelista T, Mindrup EA, Holland EJ. Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol 1994;112:1471-5
21. Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho SY, Kim HS. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 2001;33:95-102
22. Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993;53:5822-7
23. Risau W. Angiogenic growth factors. Prog Growth Factor Res 1990;2:71-9
24. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994;78:35-43
25. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995;270:815-22
26. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62
27. Shin SH, Kim JC, Chang SI, Lee H, Chung SI. Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin. Cornea 2000;19:212-7
28. Thomas G, Hall MN. TOR signalling and control of cell growth. Curr Opin Cell Biol 1997;9:782-7
29. Vermeulen PB, Dirix LY, Van Marck E, Van Oosterom AT. High endothelial cell proliferation index and high microvessel density in vascular hotspots suggest an active angiogenic process in human colorectal adenocarcinomas. Angiogenesis Group. Br J Cancer 1996;74:1506-7
30. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-6
31. Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 1982;69:475-82